WO2020086423A1 - Virus de la vaccine mutants et leur utilisation - Google Patents

Virus de la vaccine mutants et leur utilisation Download PDF

Info

Publication number
WO2020086423A1
WO2020086423A1 PCT/US2019/057134 US2019057134W WO2020086423A1 WO 2020086423 A1 WO2020086423 A1 WO 2020086423A1 US 2019057134 W US2019057134 W US 2019057134W WO 2020086423 A1 WO2020086423 A1 WO 2020086423A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccinia virus
amino acid
virion
seq
recombinant vaccinia
Prior art date
Application number
PCT/US2019/057134
Other languages
English (en)
Inventor
Xiaotong Song
Mariya VISKOVSKA
Maria Luiza GOMES MEDAGLIA
Original Assignee
Icell Kealex Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icell Kealex Therapeutics filed Critical Icell Kealex Therapeutics
Priority to US17/287,497 priority Critical patent/US20210388388A1/en
Priority to EP19877342.6A priority patent/EP3870217A4/fr
Priority to CN201980084497.0A priority patent/CN113347993A/zh
Priority to MX2021004403A priority patent/MX2021004403A/es
Priority to JP2021547043A priority patent/JP2022508942A/ja
Priority to AU2019367965A priority patent/AU2019367965A1/en
Priority to CA3117378A priority patent/CA3117378A1/fr
Priority to KR1020217015446A priority patent/KR20210108944A/ko
Priority to PCT/US2019/065303 priority patent/WO2021071534A1/fr
Publication of WO2020086423A1 publication Critical patent/WO2020086423A1/fr
Priority to IL282509A priority patent/IL282509A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La présente invention concerne des virions de virus de la vaccine (VV) recombinants qui sont résistants aux défenses antivirales et ont des activités antitumorales améliorées. Dans un mode de réalisation, les VV recombinants comprennent un ou plusieurs variants de protéines de VV qui ont des mutations au niveau d'un ou de plusieurs épitopes d'anticorps neutralisants, conférant ainsi une évacuation virale à partir des anticorps neutralisants. Dans un autre mode de réalisation, le VV recombinant est résistant à la neutralisation induite par un complément en raison de l'expression d'un régulateur de l'activation du complément (par exemple CD55). Dans un autre mode de réalisation, le VV recombinant a des activités antitumorales améliorées en raison de l'expression d'anticorps bispécifiques co-ciblant des cellules cancéreuses et des cellules effectrices de la réaction immunitaire, ou l'expression d'un polypeptide bloquant la voie PD-1. Les virions de virus de la vaccine recombinants peuvent être utilisés pour traiter le cancer chez un sujet.
PCT/US2019/057134 2018-10-22 2019-10-21 Virus de la vaccine mutants et leur utilisation WO2020086423A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US17/287,497 US20210388388A1 (en) 2018-10-22 2019-10-21 Mutant vaccinia viruses and use thereof
EP19877342.6A EP3870217A4 (fr) 2018-10-22 2019-10-21 Virus de la vaccine mutants et leur utilisation
CN201980084497.0A CN113347993A (zh) 2018-10-22 2019-10-21 突变牛痘病毒及其用途
MX2021004403A MX2021004403A (es) 2018-10-22 2019-10-21 Virus vaccinia mutantes y uso de los mismos.
JP2021547043A JP2022508942A (ja) 2018-10-22 2019-10-21 変異ワクシニア・ウイルスおよびその使用
AU2019367965A AU2019367965A1 (en) 2018-10-22 2019-10-21 Mutant vaccinia viruses and use thereof
CA3117378A CA3117378A1 (fr) 2018-10-22 2019-10-21 Virus de la vaccine mutants et leur utilisation
KR1020217015446A KR20210108944A (ko) 2018-10-22 2019-10-21 돌연변이 백시니아 바이러스 및 이의 용도
PCT/US2019/065303 WO2021071534A1 (fr) 2019-10-08 2019-12-09 Virus mutants de la vaccine et leur utilisation
IL282509A IL282509A (en) 2018-10-22 2021-04-21 Mutant vaccinia viruses and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862749102P 2018-10-22 2018-10-22
US62/749,102 2018-10-22
US201962912344P 2019-10-08 2019-10-08
US62/912,344 2019-10-08

Publications (1)

Publication Number Publication Date
WO2020086423A1 true WO2020086423A1 (fr) 2020-04-30

Family

ID=70331869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/057134 WO2020086423A1 (fr) 2018-10-22 2019-10-21 Virus de la vaccine mutants et leur utilisation

Country Status (10)

Country Link
US (1) US20210388388A1 (fr)
EP (1) EP3870217A4 (fr)
JP (1) JP2022508942A (fr)
KR (1) KR20210108944A (fr)
CN (1) CN113347993A (fr)
AU (1) AU2019367965A1 (fr)
CA (1) CA3117378A1 (fr)
IL (1) IL282509A (fr)
MX (1) MX2021004403A (fr)
WO (1) WO2020086423A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113322280A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN113322279A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种敲除d8l基因的重组痘苗病毒载体
CN113481241A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除h3l基因的重组痘苗病毒载体
CN113481240A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除l1r基因的重组痘苗病毒载体
CN114058644A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058645A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058643A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
WO2022147480A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2023118603A1 (fr) 2021-12-24 2023-06-29 Stratosvir Limited Vecteurs améliorés du virus de la vaccine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369587B (zh) * 2021-12-25 2024-03-15 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
CN116179654B (zh) * 2022-12-30 2023-09-15 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
US20090232822A1 (en) * 2005-07-21 2009-09-17 Celera Corporation Lung disease targets and uses thereof
WO2013038066A1 (fr) * 2011-09-16 2013-03-21 Oncos Therapeutics Ltd. Virus de la vaccine oncolytique modifié

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341356C (fr) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus specifique d'une infection ciblee
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US7807180B2 (en) * 2007-08-21 2010-10-05 University Of Massachusetts Poxvirus methods and compositions
WO2009048769A2 (fr) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Anticorps monoclonaux spécifiques du virus de la vaccine h3l et b5r, procédés de préparation et d'utilisation correspondants
CN102573902A (zh) * 2009-11-05 2012-07-11 分子医学和免疫学中心 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
US20090232822A1 (en) * 2005-07-21 2009-09-17 Celera Corporation Lung disease targets and uses thereof
WO2013038066A1 (fr) * 2011-09-16 2013-03-21 Oncos Therapeutics Ltd. Virus de la vaccine oncolytique modifié

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTOINE ET AL.: "The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses", VIROLOGY, vol. 244, 1998, pages 365 - 396, XP004445824, DOI: 10.1006/viro.1998.9123 *
See also references of EP3870217A4 *
STITTELAAR ET AL.: "Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies", JOURNAL OF VIROLOGY, vol. 74, no. 9, May 2000 (2000-05-01), pages 4236 - 4243, XP002503633, DOI: 10.1128/JVI.74.9.4236-4243.2000 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022147480A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique
WO2022147481A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Polythérapie d'un virus oncolytique délivrant un antigène étranger et cellule immunitaire modifiée exprimant un récepteur chimérique ciblant l'antigène étranger
CN113322280A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN113322279A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种敲除d8l基因的重组痘苗病毒载体
CN113481241A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除h3l基因的重组痘苗病毒载体
CN113481240A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除l1r基因的重组痘苗病毒载体
CN114058644A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058645A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058643A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
WO2023118603A1 (fr) 2021-12-24 2023-06-29 Stratosvir Limited Vecteurs améliorés du virus de la vaccine

Also Published As

Publication number Publication date
IL282509A (en) 2021-06-30
MX2021004403A (es) 2021-10-22
CA3117378A1 (fr) 2020-04-30
CN113347993A (zh) 2021-09-03
EP3870217A1 (fr) 2021-09-01
AU2019367965A1 (en) 2021-06-03
JP2022508942A (ja) 2022-01-19
KR20210108944A (ko) 2021-09-03
EP3870217A4 (fr) 2022-08-31
US20210388388A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
US20210388388A1 (en) Mutant vaccinia viruses and use thereof
JP5683455B2 (ja) 親和性を改変した単純ヘルペスウイルス（ｈｓｖ）、その使用および調製法
US20060127981A1 (en) Targeting viruses using a modified sindbis glycoprotein
JP2019501671A (ja) 操作された腫瘍溶解性ウイルス
JP2017508466A (ja) キメラ抗原受容体
US8753639B2 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
US11802292B2 (en) Modified orthopoxvirus vectors
KR20210094535A (ko) 4-1bbl (cd137l) 및/또는 cd40l를 암호화하는 재조합 mva의 종양내 및/또는 정맥내 투여에 의한 암의 치료 방법
JP2018512150A (ja) 癌を治療するための治療用組成物及び使用方法
JP2020518613A (ja) 癌抗原を含む改善されたｌａｍｐ構築物
KR20210111237A (ko) 암세포 표적화 영역과 hvem의 세포외 도메인의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
JP7190166B2 (ja) 改変糖タンパク質ｄを有するヘルペスウイルス
WO2021071534A1 (fr) Virus mutants de la vaccine et leur utilisation
WO2019128996A1 (fr) Lymphocyte t-car spécifique de la mésothéline exprimant un anticorps cd47, et son utilisation
JP2022512595A (ja) 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
JP6025793B2 (ja) 親和性を改変した単純ヘルペスウイルス（ｈｓｖ）、その使用および調製法
CN116133671A (zh) 重组牛痘病毒
CN112759654A (zh) 一种病毒囊膜蛋白装配系统及其方法和应用
JP7456584B2 (ja) 腫瘍標的化タンパク質又はその断片、それに結合する抗体及びその使用
US20240132913A1 (en) Modified orthopoxvirus vectors
KR20240005849A (ko) 종양용해성 hsv의 범용 재표적화
CA3195886A1 (fr) Agents therapeutiques a base d'anticorps anti-herv-k

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19877342

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021547043

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3117378

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019877342

Country of ref document: EP

Effective date: 20210525

ENP Entry into the national phase

Ref document number: 2019367965

Country of ref document: AU

Date of ref document: 20191021

Kind code of ref document: A